Qu – which, according to Parsa, is the fruit of a collaboration between a global team of experienced AI scientists, ...

How will AI continue to transform drug development? What’s next for cell and gene therapy? Who will take the crown in the ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As clinical trials advance, Ben Hargreaves finds the technology is poised to ...

Today, we live in an age of artificial intelligence (AI); more specifically, the age of generative AI (GenAI). In a recent report, 65% of respondents stated that their organisations are regularly ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE.